After clearing the first single-use duodenoscope last month, the US Food and Drug Administration (FDA) on Wednesday called on hospitals and healthcare providers to transition away from older, infection-prone duodenoscopes to newer models with disposable designs.
While acknowledging that such a transition will take time, FDA says it will “continue to work with manufacturers to increase the supply of disposable cap duodenoscopes” and promote the development of new duodenoscopes with innovative designs that will reduce the risk of infection.
FDA also said it is still working to address challenges related to the reprocessing of traditional duodenoscopes that are still in use.
In the years since, FDA has taken a number of actions resulting from its investigation into the devices, including requiring a Section 522 postmarking study for the devices; warning the three largest duodenoscope manufacturers over cleaning validation and failing to adhere to postmarketing study requirements; recalling a device commonly used to clean duodenoscopes; and urging industry to move to less risky designs.
While industry has heeded FDA’s call to develop partially and fully disposable duodenoscopes, some researchers have questioned how the transition will affect health care spending and whether new designs and reprocessing methods for reusable duodenoscopes could be sufficient to reduce infection risks.